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Background and Objectives. Patients with angioim-
munoblastic T-cell lymphoma (AIL) have a poor prognosis with
conventional treatment.
Design and Methods. We initiated an EBMT-based survey
studying the impact of high-dose chemotherapy (HDCT) and
autologous hematopoietic stem cell transplantation in patients
with AIL. Data on 29 patients, who were transplanted between
1992 and 1998 in 16 transplant centers, were collected on
standardized documentation forms.
Results. The median age at transplantation was 53 years.
HDCT was given as part of 1st-line therapy (N=14; 48%) or
2nd/3rd-line therapy (N=15; 52%). Regimens for the mobiliza-
tion of peripheral blood stem cells (PBSC) included VIPE (N=7;
26%), DexaBEAM (N=6; 22%), CHOP-like regimens (N=6;
22%), other regimens  (N=5; 19%) or alternatively growth fac-
tor alone (N=3; 11%). The median yield of PBSC was 3.8×106
CD34+cells/kg. Two patients received autologous bone mar-
row. The HDCT consisted of BEAM-type regimens in 16 patients,
ICE-type regimens in 7, and other regimens in 6 patients. There
was one treatment-related death. The rate of complete remis-
sions increased from 45% before HDCT to 76% after HDCT. As
of January 2003, after a median observation time of living
patients of 5 years (range 2.5 to 10 years), 14 patients have
died (13 from progressive disease), and 15 patients are alive.
The probability of 5-year overall and event-free survival was
44% (95% CI, 22% to 66%) and 37% (95% CI, 17% to 57%),
respectively. Long-term disease-free survival was observed in
patients transplanted during 1st-line treatment as well as in the
context of 2nd/3rd-line therapy.
Interpretation and Conclusions. There is evidence that AIL
is susceptible to high-dose chemotherapy. HDCT and autolo-
gous stem cell transplantation should be considered in select-
ed patients with AIL.
Key words: angioimmunoblastic T-cell lymphoma, high-dose
chemotherapy, autologous stem cell transplantation.
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Angioimmunoblastic T-cell-lymphoma (AIL) is oneof the mature T-cell neoplasms defined in theREAL- and WHO-classifications.1 Lymph node his-
tology of this disease is characterized by a typical mor-
phologic picture with effacement of the nodal archi-
tecture by a polymorphic inflammatory infiltrate con-
taining small lymphocytes, large lymphoid blasts and
follicular dendritic cells, as well as marked vascular pro-
liferation. According to the Non-Hodgkin’s Lymphoma
Classification Project the frequency of AIL among cas-
es referred to expert hematopathologists ranges
between 1% and 2% of all non-Hodgkin´s lymphomas
in Europe.2 Although research on the etiology, patho-
physiology and clinical behavior of AIL is hampered by
its rarity and the difficulty in identifying the neoplastic
cell population, considerable progress has been made
during the last decade.2 AIL was initially supposed to be
the result of an abnormal immune reaction. However,
due to the frequent finding of T-cell receptor gene
rearrangements and distinct cytogenetic aberrations
(trisomy 3 and/or 5), it is now clearly recognized that
AIL is a malignant T-cell lymphoma.4-6
At presentation, 90% of patients with AIL have
advanced disease and the median age at initial diag-
nosis is about 65 years.7 AIL usually has a very aggres-
sive course. However, as it is a rare disease there are no
generally accepted treatment guidelines of proven
effectiveness. Most clinicians choose intensive adri-
amycin-containing chemotherapy programs. However,
the probability of 5-year event-free survival even after
intensive chemotherapy is below 30%.8-12
Given the increasing experience in applying high-dose
chemotherapy (HDCT) and autologous stem cell trans-
plantation to improve the prognosis of patients with
high-grade B-cell lymphomas, we asked whether HDCT
may also be advantageous for selected patients with
AIL. We, therefore, performed an international survey
and retrospectively evaluated the clinical characteris-
tics at initial diagnosis, treatment-strategies prior to
HDCT, PBSC mobilization, status at transplantation,
hematopoietic regeneration, response and long-term
outcome of patients with AIL who had received HDCT.
Design and Methods
Data collection and selection of patients
In June 1999 272 EBMT bone marrow transplant cen-
ters were asked to contribute data to a survey on
patients with AIL who had received high-dose chemo-
therapy and an autologous stem cell transplant. Uni-
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form standardized questionnaires were sent to cen-
ters which wanted to participate. In September
2002 follow-up information was requested for
every patient.
Definitions
The stage of disease was determined according to
the Ann Arbor classification system.13 The age-
adjusted International Prognostic Factor Index for
patients aged below 60 years was applied.14 First-
line treatment strategies were classified as follows:
a strategy of watch and wait was defined by a min-
imum interval of one month between diagnosis and
the onset of any specific treatment, including the
administration of corticosteroids. A therapeutic tri-
al of corticosteroids without chemotherapy had to
last for a minimum of one month.
Complete remission (CR) was defined as total dis-
appearance of all evidence of tumor; partial remis-
sion (PR) as a >50% reduction in the sum of the
products of the longest diameters of measurable
lesions; stable disease (SD) as no objective decrease
in the tumor measurements qualifying as partial
remission and no objective increase qualifying as
progressive disease; progressive disease (PD) as a
>25% increase of the product of the longest diam-
eters of any measurable lesion or the appearance
of new lesions. Relapse mortality after HDCT was
defined as death related to progressive disease,
whereas treatment-related mortality was defined
as death from any other cause.
Statistical analysis
Data were analyzed as of January 2003. Survival
probabilities were calculated according to the
method of Kaplan and Meier. Overall survival was
calculated from the date of transplantation to the
date of death or the date of last follow-up. Event-
free survival was taken from the date of trans-
plantation until treatment failure or death from
any cause. Patients with stable or progressive dis-
ease at first evaluation after HDCT were included
in the calculation with an event-free survival of
zero days.15 The χ2 test was used for the compari-
son of proportions and the log-rank test was used
for the comparison of time-dependent events.
Results
Patients
Sixteen EBMT-centers reported data on 29
patients (Table 1). At inital diagnosis the median
age of the patients was 51 years. Nineteen were
male, 10 were female. At inital diagnosis only one
patient (3%) had limited disease (Ann Arbor stage
≤ II) while 28 patients (97%) had stage III or IV
disease.13 According to the age-adjusted Interna-
tional Prognostic Factor Index (IPI) 79% of patients
were at high intermediate or high risk.14 Bone mar-
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Table 1. Baseline characteristics at initial diagnosis.
Characteristics
Median age at diagnosis (range) [yrs] 51 (20 to 59)
Median age at HSCT (range) [yrs] 53 (20 to 60)
Sex (male/female) 19 (65%)/10 (35%)
Diagnosis based on:
detailed report  15/29 (52%)
(including immunophenotype)
reference histology 8/29 (27%)
brief pathological report 6/29 (21%)













Age-adjusted International Prognostic factor Index (N=24)
low 0 (0%)
low intermediate 5 (21%)
high intermediate 8 (33%)
high 11 (46%)
Bone marrow involvement 12/29 (41%)












Any autoimmune phenomena 10/29 (34%)
Cold agglutinins/cryoglobulins 6/29 (21%)
Coombs’-pos. AIHA 8/17 (47%)
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row was involved in 12 patients (41%). B-symp-
toms were present in 20 patients (69%). Lactate
dehydrogenase (LDH) was elevated above the upper
normal range in 20 of 27 patients (74%). Extran-
odal involvement was found in 17/29 patients
(59%) in the following organs: liver (21%), lung
(10%), skin (10%), and intestine (7%). Patients
showed signs and symptoms known to be associ-
ated with a diagnosis of AIL, such as pruritus (37%),
effusions (36%), skin rash (20%) and peripheral
edema (20%) as predominant features. Autoim-
mune phenomena, such as Coombs’-positive
hemolytic anemia or the presence of cold agglu-
tinins or cryoglobulins, were diagnosed in 10
patients (34%).
Treatment prior to HDCT
First-line treatment consisted of chemotherapy in
22 patients (76%), while 4 patients (14%) received
corticosteroids without chemotherapy and a watch-
and-wait strategy was applied in 3 patients (10%).
No patient received radiotherapy as first-line treat-
ment. Sixteen patients (55%) received the CHOP
regimen as first-line chemotherapy and in 12
patients (41%) more intensive chemotherapies were
administered (Table 2).8,16 First-line chemotherapy
resulted in an overall response rate of 79% (34% CR
and 45% PR). HDCT was administered as a part of
first-line treatment in 14 (48%) patients.
Fifteen patients received HDCT as part of 2nd
(N=10; 34%) or 3rd-line (N=5; 18%) treatment. In
these patients the salvage chemotherapies at first
relapse consisted of DexaBEAM (40%), CHOP
(27%), DHAP ± etoposide (13%) and other regi-
mens in 3 patients (Table 3). Salvage chemothera-
py resulted in an overall response rate of 87% (40%
CR and 47%PR).17-19 Two patients (7%) received
local radiotherapy as part of their 2nd line treat-
ment. Five patients received HDCT as part of 3rd-
line treatment after a variety of salvage chemo-
therapies.
Stem cell harvest
The autologous hematopoietic stem cell graft
consisted of bone marrow in 2/29 (7%) patients,
and of peripheral blood stem cells (PBSC) in 27/29
(93%) patients. Regimens used for PBSC mobiliza-
tion were VIPE (7/27; 26%), DexaBEAM (6/27;
22%), CHOP-like (6/27; 22%), high-dose cyclo-
phosphamide (4/27; 15%) and mitoxantrone/cy-
tarabine (1/27; 4%) each in combination with
granulocyte colony-stimulating factor (G-CSF) or
G-CSF alone (3/27, 11%).17,20 The stem cell products
were unmanipulated in 19 patients (70%), while 8
patients (30%) received CD34+ selected PBSC.
Conditioning regimens and HSCT
Patients received HDCT and HSCT between 1992
and 1998. At transplantation the median age was
53 years (range, 20 to 60 years). Conditioning pri-
or to HSCT was carried out with BEAM or BEAM-
like regimens in 16 patients (56%), ICE or ICE-like
regimens in 7 patients (24%), TBI/CY or BU/CY in
J. Schetelig et al.
Table 2. Results of 1st-line chemotherapy (N=29).
Response
CHOP (N=16) 4×CR (25%)
8×PR (50%)
4×SD/PD (25%)
Intensive combination 5×CR (42%)
chemotherapies* (N=12) 5×PR (42%)
2×SD/PD (16%)
Others (N=1) 1×CR (100%)
*ProMACE-CytaBOM: prednisone, doxorubicin, cyclophosphamide,
and etoposide, followed by cytarabine, bleomycin, vincristine,
and methotrexate with leucovorin rescue;16 COPBLAM-IMVP16:
cyclophosphamide, vincristine, bleomycin, adriamycin,
procarbazine, prednisone alternating with ifosfamide,
methotrexate, etoposide;8 VACOP-B: etoposide, doxorubicin,
cyclophosphamide, vincristine, prednisone, bleomycin;26
CHOEP: CHOP combined with etoposide.16
Table 3. Results of salvage chemotherapy at first
relapse (N=15).
Response
DexaBEAM (N=6) 3×CR (50%)
3×PR (50%)
CHOP (N=4) 1×CR (25%)
1×PR (25%)
2×SD/PD (50%)
DHAP ± Etoposide (N=2) 1×CR (50%)
1×PR (50%)
Others (N=3) 1×CR (33%)
2×PR (67%)
DexaBEAM: dexamethasone, BCNU, etoposide, cytarabine,
melphalan;17 CHOP: cyclophosphamide, vincristine, adriamycin,
prednisolone;16 DHAP: dexamethasone, cytarabine, cisplatin.18,19
Table 4. High-dose-chemotherapy regimens (N=29).
BEAM/BEAM-like 16 (56%)
ICE/ICE-like 7 (24%)
TBI/CY or BU/CY 3 (10%)
Others 3 (10%)
BEAM: BCNU, etoposide, cytarabin, melphalan;17 TBI: total body
irradiation; CY: cyclophosphamide; BU: busulfan.22
High-dose chemotherapy in AIL
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3 patients (10%) and miscellaneous regimens in 3
patients (10%) (Table 4).17,21,22 The mononuclear cell
counts in the two patients who received autolo-
gous bone marrow, were 2.2 and 2.8×106 cells /kg
body weight. PBSC products contained a median
number of 3.8×106 CD34 cells/kg (range, 1.0 to
13.6×106 CD34 cells/kg). Supportive care after
transplantation was provided according to differ-
ing protocols of each participating institution.
Hematologic regeneration
After transplantation all patients received
growth factors to accelerate hematopoietic regen-
eration. Twenty-seven patients (93%) received G-
CSF and two patients (7%) received granulocyte-
macrophage colony-stimulating factor. Data on
hematologic regeneration were missing in two
patients and one patient died before platelet
regeneration occurred. In the evaluable patients
regeneration of granulocytes to > 0.5×109/L took a
median of 11 days (range, 10 to 55 days) and
regeneration of platelets to > 25×109/L took a
median of 14 days (9 to 55 days).
Response to HDCT
Immediately before HDCT 13 patients (45%)
were in CR, 11 patients (38%) in PR, and 5 patients
(17%) had SD/PD (Table 5). After HDCT 22 patients
(76%) were in CR, 3 patients (10%) in PR, and 4
patients (14%) had SD/PD. The CR rates after trans-
plantation in patients who were treated with HDCT
as part of first-line, 2nd-line and 3rd-line therapy
were 86%, 70% and 60%, respectively (p=0.446).
Of 5 patients with stable or progressive disease at
transplantation four patients achieved a remission
and one out of these four patients is still alive in
continuous CR four years after transplantation.
Survival
Complete follow-up was available for 28
patients, while one patient was lost from follow-
up 2 years after transplantation while in continu-
ous CR. As of January 2003 after a median obser-
vation time of 5 years (range 2.5 to 10 years) in liv-
ing patients, 14 patients had died and 15 were
alive. Thirteen patients died due to relapse and one
patient died from CMV-pneumonia 43 days after
transplantation.
The 5-year probabilities of overall survival and
of event-free survival (Figure 1) were 44% (95% CI,
22% to 66%) and 37% (95% CI, 17% to 57%),
respectively. Of 22 patients who achieved a com-
plete remission after HDCT, nine patients (41%)
experienced a relapse and the 5-year probabilities
of overall survival and event-free survival were
62% (95% CI, 48% to 86%) and 49% (95% CI,
24% to 74%), respectively. At last follow-up, five
patients were in continuous CR for more than 5
years (range, 6 to 10 years after HSCT). The 5-year
probabilities of overall and event-free survival in
patients who were transplanted as first-line ther-
apy compared to those who were transplanted as
second- or third-line therapy were 60% and 37%
compared to 44% and 39%, respectively (Figures 2
and 3). The 5-year probabilities of event-free sur-
vival according to the International Prognostic Fac-
tor Index were 60% (95% CI, 18% to 100%) for
patients at low intermediate risk, 42% (95% CI,
3% to 81%) for patients at high intermediate risk
and 25% (95% CI, 0% to 55%) for patients at high
risk (log-rank, p=0.2572).
Discussion
Angioimmunoblastic T-cell lymphoma is a very
rare disease. The median age at initial diagnosis is
about 65 years and currently patients with AIL are
generally considered to have a poor prognosis.
Despite past reports on individual patients with
benign disease courses, the reported median sur-
vival is 20 months and the 4-year probability of
overall survival is only about 30%.8-10,12 Patients
with AIL are most often treated like patients with
aggressive B-cell lymphoma. Data on second-line
treatment strategies for patients with relapsed AIL
are rare. However, there have been case reports on
prolonged disease-free survival after HDCT and
autologous stem cell transplantation in patients
with relapsed AIL.12,23,24 We, therefore, performed a
survey in order to determine the feasibility and effi-
cacy of HDCT in patients with AIL.
Indirect evidence that mobilization of PBSC in
patients with AIL is comparable to mobilization in
patients with more conventional diagnoses comes
from the fact that PBSC harvest was successful in 9
patients transplanted at first relapse and in 5
patients transplanted at second relapse. Furthermore
we did not receive reports on difficult or impossible
stem cell mobilization in patients with AIL.
The potential of high-dose chemotherapy to
Table 5. Response status before and after HDCT.
N=29 Prior HDCT Max response
after HDCT
First-line 14 CR 7 CR 12
PR 6 PR 1
NC/PD 1 NC/PD 1
Second-line 10 CR 4 CR 7
PR 5 PR 2
NC/PD 1 NC/PD 1
Third-line 5 CR 2 CR 3
PR 0 PR 0
NC/PD 3 NC/PD 2
J. Schetelig et al.
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Figure 1. Overall and event-free sur-
vival. The probability of 5-year over-
all survival was 44% (95% CI 22% to
66%) and that of 5-year event-free
survival was 37% (95% CI 17% to
57%).
Figure 3. Event-free survival according
to treatment strategy. The probability
of EFS was 37% (95% CI 8% to 66%)
for patients in whom HDCT was
applied in 1st line therapy and 39%
(95% CI 13% to 65%) in those in whom
it was administered in more advanced
disease (log-rank, p=0.6075).
Figure 2. Overall survival according
to treatment strategy. The probabili-
ty of 5-year overall survival was 60%
(95% CI 30% to 90%) for patients in
whom HDCT was applied as 1st line
therapy and 44% (95% CI 18% to
70%) in those in whom it was admin-
istered as 2nd/3rd line therapy (log-
rank, p=0.1699).
Overall survival 15/29
Event-free survival 12/29 
HDT as 1st line therapy 
HDT as 2nd/3rd line therapy 






































1 2 3 4 5 6 7 8 9 10
Years after HSCT
1 2 3 4 5 6 7 8 9 10
Years after HSCT



















HDT as 1st line therapy 
High-dose chemotherapy in AIL
haematologica/journal of hematology vol. 88(11):november 2003 1277
increase the rate of complete remissions from 45%
before HDCT to 76% after it is of special impor-
tance. Furthermore, the rate of relapse was very
low in patients achieving a complete remission
after HDCT. Among the 22 patients who achieved
a complete remission after HDCT the 5-year prob-
ability of overall survival was 62% (95% CI, 48%
to 86%). To date, five patients are in continuous
complete remission with a follow-up of more than
5 years. These excellent results can be interpreted
as a susceptibility of AIL to escalated doses of cyto-
static agents and suggest that long-term event-
free survival and cure can be achieved in selected
patients with HDCT. Bearing in mind that half of
the patients were transplanted in first or even sec-
ond relapse, and that their median age was 53
years at HSCT, the 5-year overall survival probabil-
ity of 44% for the whole group compares very
favorably with published results, especially when
comparing data on second-line treatment.8,9,11
Of 14 patients with AIL receiving second-line
therapy, reported by Pautier et al. in 1999, only 3
patients obtained a durable second complete
remission.12 It is of interest that two of these three
patients had received HDCT and autologous HSCT.
In addition to reports on long-term disease-free
survival after HDCT, there is evidence that the
adverse prognostic influence of the T-phenotype
in aggressive lymphoma could be overcome by
dose-escalation strategies. Gisselbrecht et al.
reported a 5-year overall survival rate of 41% in
patients with a variety of aggressive lymphomas
of T-phenotype. This compared with a rate of 53%
in patients with lymphoma of B-phenotype
(p=0.0004) included in the LNH87-trials of the
Groupe d’Etudes des Lymphomes de l’Adulte.11 How-
ever, for the subgroup of 16 patients with a T-phe-
notype who had received HDCT and autologous
HSCT, he reported similar survival rates to those in
patients with aggressive B-cell lymphoma.
Rodriguez et al. retrospectively analyzed data on 36
patients with peripheral T-cell lymphoma (REAL
classification) who had received HDCT and autol-
ogous HSCT after relapse and found a 3-year over-
all survival rate of 36%, similar to that in patients
with relapsed B-cell lymphoma.25 This observation
was supported by retrospective data published by
Blystad et al.23 Blystad analyzed data on patients
with aggressive lymphoma of T-cell phenotype
who had received HDCT and autologous HSCT and
found overall survival rates similar to those of B-
cell lymphoma. Our data, therefore, fit within an
emerging picture that the poor prognostic impli-
cation of T-phenotype in aggressive lymphoma can
be overcome by HDCT.
However, our data must to be interpreted with
caution. There is a systematic bias from including
patients who had received HDCT. We do not have
information on patients who should have received
HDCT but failed salvage chemotherapy.
Future trials need to answer the question of
whether HDCT and autologous HSCT should be
applied as first-line strategy for patients with AIL.
However, we observed long-term event-free sur-
vival even in patients transplanted in relapse. A
conservative approach would, therefore, be to offer
conventional treatment as first-line strategy and
HDCT and autologous HSCT in first relapse.
In conclusion, HDCT and autologous HSCT in AIL
as first-line or as a part of a salvage strategy induces
a high remission rate and long-term event-free sur-
vival in selected patients. This observation argues in
favor of a dose-response relationship in AIL. The
option of HDCT should be offered to patients with
relapsed AIL, eligible for intensive treatment strate-
gies. Our data should encourage the inclusion of
patients with AIL into ongoing prospective multi-
center trials evaluating the role of HDCT.
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